Photo from wikipedia
Recently, some trials challenged the favorable consequences of levosimendan toward renal function. A recent meta-analysis by Long et al. evaluated 28 studies in 5,069 patients [1]. Levosimendan reduced the serum… Click to show full abstract
Recently, some trials challenged the favorable consequences of levosimendan toward renal function. A recent meta-analysis by Long et al. evaluated 28 studies in 5,069 patients [1]. Levosimendan reduced the serum creatinine (sCr) and the risk of acute kidney injury (AKI) patients with left ventricular dysfunction (LVD) compared with the control group [1]. The reduction of sCr was more pronounced in patients with a relatively high baseline sCr level. Furthermore, levosimendan therapy was associated with the improvement of glomerular filtration rate (GFR) and urine output [1]. Long et al. proposed a number of mechanisms explaining their findings [1]. To further elucidate these mechanisms for bedside clinicians, we critically evaluate them.
Journal Title: Expert Opinion on Drug Safety
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!